<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Hematological Models

Superior Hematological Models of AML for research.

Unique Collection of Hematological Models for Reliable Insights

Champions has established a proprietary platform for modeling leukemias (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia), non-Hodgkins lymphomas (Diffuse Large B-cell lymphoma, and Mantle Cell Lymphoma), and Multiple Myeloma from primary patients. This platform enables clients to assess the efficacy of novel therapeutic strategies in models that closely mirror the disease biology and recapitulate the diversity of the patient population.

  • Largest engraftable hematological repository of primary AML, ALL, DLBCL, MCL, and MM models

  • Derived from leukapheresis to retain the molecular and pathological profile of the original patient

  • Extensive clinical annotations and deep molecular characterization data are available in Lumin

The Industry's Most Deeply Characterized Hematological Models

Champions uses primary leukemia samples, engrafted systemically to preserve the unique patient characteristics including cellular heterogeneity, otherwise lost in passaged models. The efficacy of experimental therapeutic agents is measured as changes in engraftment in relevant tissue compartments.  

These models are clinically relevant and are established from different disease-stage tumors. Many of the patients were pretreated using standard-of-care therapies and the latest targeted agents.

Models are clinically annotated and characterized by NGS, Proteomics, Phospho-proteomics, and in vivo drug response testing, available in Lumin. A diverse dataset can be utilized to assess biomarkers of response or non-response within these indications and to model defined patient cohorts co-clinically.

AML in vivo engraftment results.

Hematological Model Endpoints


Body Weight-1
Western Blot
In this white paper, we provide an overview of the most common hematologic malignancies, highlight cutting-edge technologies being used to understand these blood cancers, and apply these insights toward the development of novel therapeutics and diagnostics.

Tab Imges_Medium5